Hanno Riess

21.3k total citations · 4 hit papers
319 papers, 13.5k citations indexed

About

Hanno Riess is a scholar working on Oncology, Surgery and Internal Medicine. According to data from OpenAlex, Hanno Riess has authored 319 papers receiving a total of 13.5k indexed citations (citations by other indexed papers that have themselves been cited), including 145 papers in Oncology, 99 papers in Surgery and 62 papers in Internal Medicine. Recurrent topics in Hanno Riess's work include Pancreatic and Hepatic Oncology Research (88 papers), Venous Thromboembolism Diagnosis and Management (62 papers) and Cancer Genomics and Diagnostics (34 papers). Hanno Riess is often cited by papers focused on Pancreatic and Hepatic Oncology Research (88 papers), Venous Thromboembolism Diagnosis and Management (62 papers) and Cancer Genomics and Diagnostics (34 papers). Hanno Riess collaborates with scholars based in Germany, United States and United Kingdom. Hanno Riess's co-authors include Helmut Oettle, Peter Wust, Bert Hildebrandt, R. Félix, Beate Rau, Bernd Dörken, Johanna Gellermann, P. Neuhaus, Uwe Pelzer and Klaus Gellert and has published in prestigious journals such as The Lancet, JAMA and Journal of Clinical Oncology.

In The Last Decade

Hanno Riess

308 papers receiving 13.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Adjuvant Chemotherapy With Gemcitabine vs Observation in Patients Undergoing Curative-Intent Resection of Pancreatic Cancer

2007 1.8k citations Helmut Oettle, P. Neuhaus et al. profile →
Hyperthermia in combined treatment of cancer

2002 1.5k citations Peter Wust, Bert Hildebrandt et al. profile →
Adjuvant Chemotherapy With Gemcitabine and Long-term Outcomes Among Patients With Resected Pancreatic Cancer

2013 1.3k citations Helmut Oettle, P. Neuhaus et al. profile →
Clinical experiences with magnetic drug targeting: a phase I study with 4'-epidoxorubicin in 14 patients with advanced solid tumors.

1996 508 citations Hanno Riess, Bernd Dörken et al. PubMed profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Hanno Riess Germany	49	7.0k	3.1k	2.5k	2.5k	2.4k	319	13.5k
Barry A. Siegel United States	82	4.8k 0.7×	4.0k 1.3×	7.3k 2.9×	1.3k 0.5×	2.0k 0.8×	359	23.1k
Peter F. Hahn United States	73	2.6k 0.4×	7.0k 2.3×	4.0k 1.6×	2.6k 1.1×	1.9k 0.8×	313	17.4k
S. Nahum Goldberg United States	74	3.8k 0.5×	5.6k 1.8×	6.9k 2.7×	6.8k 2.8×	4.6k 1.9×	312	24.6k
Chusilp Charnsangavej United States	58	5.5k 0.8×	4.0k 1.3×	3.8k 1.5×	760 0.3×	2.6k 1.1×	198	11.2k
Steven A. Curley United States	82	10.4k 1.5×	8.0k 2.6×	4.3k 1.7×	3.3k 1.3×	4.6k 1.9×	309	24.4k
Michael C. Soulen United States	53	2.9k 0.4×	2.9k 0.9×	3.4k 1.3×	1.2k 0.5×	2.5k 1.0×	258	10.5k
Riad Salem United States	83	5.3k 0.8×	6.6k 2.1×	6.9k 2.7×	1000 0.4×	8.4k 3.5×	431	25.3k
Jens Ricke Germany	47	2.2k 0.3×	2.8k 0.9×	3.2k 1.3×	1.4k 0.6×	1.9k 0.8×	525	10.8k
Armando Santoro Italy	87	17.8k 2.5×	3.8k 1.2×	13.8k 5.4×	1.0k 0.4×	2.6k 1.1×	924	34.7k
Bernd Dörken Germany	81	8.6k 1.2×	1.1k 0.4×	2.3k 0.9×	536 0.2×	1.4k 0.6×	412	22.0k

Countries citing papers authored by Hanno Riess

Since Specialization

Citations

This map shows the geographic impact of Hanno Riess's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hanno Riess with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hanno Riess more than expected).

Fields of papers citing papers by Hanno Riess

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hanno Riess. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hanno Riess. The network helps show where Hanno Riess may publish in the future.

Co-authorship network of co-authors of Hanno Riess

This figure shows the co-authorship network connecting the top 25 collaborators of Hanno Riess. A scholar is included among the top collaborators of Hanno Riess based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hanno Riess. Hanno Riess is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Sinn, Marianne, Uwe Pelzer, Hanno Riess, et al.. (2024). KRT81 and HNF1A expression in pancreatic ductal adenocarcinoma: investigation of predictive and prognostic value of immunohistochemistry‐based subtyping. The Journal of Pathology Clinical Research. 10(3). e12377–e12377. 1 indexed citations

Rauch‐Kröhnert, Ursula & Hanno Riess. (2022). Antikoagulation bei „coronavirus disease 2019“ (COVID-19) – Gesichertes und Kontroverses. Der Internist. 63(4). 453–460. 2 indexed citations

Mones, Jodi V., Michael B. Streiff, Alok A. Khorana, et al.. (2021). Rivaroxaban thromboprophylaxis for gastric/gastroesophageal junction tumors versus other tumors: A post hoc analysis of the randomized CASSINI trial. Research and Practice in Thrombosis and Haemostasis. 5(5). e12549–e12549. 9 indexed citations

Sinn, M., Jan Budczies, Frédérik Damm, et al.. (2017). TP53 mutation predicts sensitivity to adjuvant gemcitabine in pancreatic cancer: Results from the CONKO-001 study. Annals of Oncology. 28. v251–v251. 3 indexed citations

Trappe, Ralf Ulrich, Sylvain Choquet, Petra Reinke, et al.. (2007). Salvage Therapy for Relapsed Posttransplant Lymphoproliferative Disorders (PTLD) With a Second Progression of PTLD After Upfront Chemotherapy: The Role of Single-Agent Rituximab. Transplantation. 84(12). 1708–1712. 30 indexed citations

Trappe, Ralf Ulrich, Sylvain Choquet, Stephan Oertel, et al.. (2007). Efficacy and safety of sequential treatment with rituximab and CHOP chemotherapy in B-cell PTLD: Results of a prospective international phase II study. Queensland's institutional digital repository (The University of Queensland). 1 indexed citations

Babel, Nina, Athanasios Vergopoulos, Ralf Ulrich Trappe, et al.. (2007). Evidence for Genetic Susceptibility Towards Development of Posttransplant Lymphoproliferative Disorder in Solid Organ Recipients. Transplantation. 84(3). 387–391. 36 indexed citations

Schulze, Tobias, Peter Wust, Johanna Gellermann, et al.. (2006). Influence of neoadjuvant radiochemotherapy combined with hyperthermia on the quality of life in rectum cancer patients. International Journal of Hyperthermia. 22(4). 301–318. 21 indexed citations

Hildebrandt, Bert, S. Hegewisch-Becker, Thoralf Kerner, et al.. (2004). Current status of radiant whole-body hyperthermia at temperatures >41.5°C and practical guidelines for the treatment of adults. The German ‘Interdisciplinary Working Group on Hyperthermia’. International Journal of Hyperthermia. 21(2). 169–183. 43 indexed citations

10.

Hildebrandt, Bert, Peter Wust, Lutz Lüdemann, et al.. (2004). Regional pelvic hyperthermia as an adjunct to chemotherapy (oxaliplatin, folinic acid, 5-fluorouracil) in pre-irradiated patients with locally recurrent rectal cancer: a pilot study. International Journal of Hyperthermia. 20(4). 359–369. 10 indexed citations

11.

Koppenhagen, K., A. Tolle, B. Kemkes‐Matthes, et al.. (2003). Fixed-dose, body weight-independent subcutaneous low molecular weight heparin Certoparin compared with adjusted-dose intravenous unfractionated heparin in patients with proximal deep venous thrombosis. Thrombosis and Haemostasis. 90(8). 252–259. 25 indexed citations

12.

Oettle, Helmut & Hanno Riess. (2002). Gemcitabine in combination with 5-fluorouracil with or without folinic acid in the treatment of pancreatic cancer. Cancer. 95(S4). 912–922. 33 indexed citations

13.

Oertel, Stephan, Markus Ruhnke, Ioannis Anagnostopoulos, et al.. (1999). TREATMENT OF EPSTEIN-BARR VIRUS-INDUCED POSTTRANSPLANTATION LYMPHOPROLIFERATIVE DISORDER WITH FOSCARNET ALONE IN AN ADULT AFTER SIMULTANEOUS HEART AND RENAL TRANSPLANTATION. Transplantation. 67(5). 765–767. 24 indexed citations

14.

Sodian, Ralf, et al.. (1998). Heparin induced thrombocytopenia. Experiences in 12 heart surgery patients.. PubMed. 43(5). M430–3. 19 indexed citations

15.

Himmelreich, Gabriele, Marianne Jochum, Wolf O. Bechstein, et al.. (1994). MEDIATORS OF LEUKOCYTE ACTIVATION PLAY A ROLE IN DISSEMINATED INTRAVASCULAR COAGULATION DURING ORTHOTOPIC LIVER TRANSPLANTATION. Transplantation. 57(3). 354–358. 14 indexed citations

16.

Himmelreich, Gabriele, et al.. (1994). Thrombomodulin: A marker for endothelial damage during orthotopic liver transplantation. American Journal of Hematology. 47(1). 1–5. 20 indexed citations

17.

Stiegler, H., et al.. (1989). Thrombectomy, Lysis, or Heparin Treatment: Concurrent Therapies of Deep Vein Thrombosis. Seminars in Thrombosis and Hemostasis. 1 indexed citations

18.

Hiller, Erhard, et al.. (1986). Successful treatment with high-dose intravenous immunoglobulin in a patient with spontaneous inhibitor to factor VIII. Annals of Hematology. 52(2). 123–126. 11 indexed citations

19.

Riess, Hanno, et al.. (1985). Protein C antigen in prothrombin complex concentrates: Content, recovery and half life. Annals of Hematology. 50(5). 303–306. 11 indexed citations

20.

Hiller, Erhard, Hanno Riess, R. Hafter, & H. Graeff. (1980). Evaluation of hypercoagulability after remission induction chemotherapy of acute leukemia. Annals of Hematology. 41(5). 359–366. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact